Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLI1 | P08151 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | CYP46A1 | Q9Y6A2 | 3/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4760474 | 1.00 | GLI1 (0.35) | GLI1SMYD3BCHEDPP4MME | |
| SCHEMBL4103676 | 1.00 | GLI1 (0.35) | GLI1SMYD3BCHEDPP4MME | |
| Hydrochloric Acid SCHEMBL2804477 | 0.98 | GLI1 (0.34) | GLI1SMYD3BCHEDPP4MME | |
| Hydrochloric Acid SCHEMBL13275366 | 0.98 | GLI1 (0.34) | GLI1SMYD3BCHEDPP4MME | |
| Hydrochloric Acid SCHEMBL17889948 | 0.98 | GLI1 (0.34) | GLI1SMYD3BCHEDPP4MME | |
| SCHEMBL197080 | 0.87 | — | — | |
| SCHEMBL21545609 | 0.87 | GLI1 (0.41) | GLI1BCHEDPP4MMECYP2D6 | |
| SCHEMBL4760467 | 0.86 | DPP4 (0.34) | GLI1BCHEDPP4 | |
| SCHEMBL3346344 | 0.81 | SMN1; SMN2 (0.42) | GLI1BCHEDPP4MMECYP2D6 | |
| Carbamic Acid SCHEMBL11685067 | 0.81 | GLI1 (0.35) | GLI1BCHEDPP4MMECYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4415816-B1 | PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A | BIOSPLICE THERAPEUTICS INC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12545685-B2 | Dispiropyrrolidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-02-10 | — | — | US | disclosed |
| EP-4611890-A1 | 4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | BioSplice Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250171466-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2025-05-29 | — | — | US | disclosed |
| CN-119604506-A | 4-Alkoxypyrrolo [2,1-f ] [1,2,4] triazines, preparation and use thereof | 拜斯丽治疗有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-12134625-B2 | Pyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| EP-4415816-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A | BioSplice Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| CN-118488954-A | Pyrrolo [2,1-F ] [1,2,4] triazine derivatives as DYRK1A inhibitors | 拜斯丽治疗有限公司 | 2024-08-13 | — | — | CN | disclosed |
| US-20240199649-A1 | 4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | BIOSPLICE THERAPEUTICS, INC. | 2024-06-20 | — | — | US | disclosed |
| WO-2024097391-A1 | 4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | BIOSPLICE THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| WO-2010108059-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE HISTAMINE H4 RECEPTOR | INCYTE CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
| US-20100173888-A1 | Nicotinamide Derivatives | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
| US-7683057-B2 | 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (1-acetyl-piperidin-4-yl)-amide; inhibition of 5' AMP-activated protein kinase (AMPK) | TYROGENEX, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683057-B2 | 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (1-acetyl-piperidin-4-yl)-amide; inhibition of 5' AMP-activated protein kinase (AMPK) | TYROGENEX, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| WO-2009153720-A1 | NICOTINAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
| US-20090137658-A1 | BENZENESULFONIC ACID SALT COMPOUNDS | TANABE SEIYAKU CO.,LTD. | 2009-05-28 | — | — | US | disclosed |
| US-20090137658-A1 | BENZENESULFONIC ACID SALT COMPOUNDS | TANABE SEIYAKU CO.,LTD. | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199649-A1 | 4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK2, DYRK1B | GLI1 1799/4885SMYD3 4307/4885BCHE 4437/4885 |
| US-12545685-B2 | Dispiropyrrolidine derivatives | TP53, MDM2, TP53BP1 | GLI1 1162/4885SMYD3 3857/4885BCHE 4016/4885 |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | HRH4, HRH2, HRH1 | GLI1 1592/4885SMYD3 2099/4885BCHE 1237/4885 |
| US-20090137658-A1 | BENZENESULFONIC ACID SALT COMPOUNDS | SLC5A2, SLC5A1, TST | GLI1 1772/4885SMYD3 1505/4885BCHE 598/4885 |
| US-20100173888-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | GLI1 4739/4885SMYD3 4450/4885BCHE 2882/4885 |
| US-20250171466-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK2, DYRK1B | GLI1 1971/4885SMYD3 4499/4885BCHE 4639/4885 |
| US-12134625-B2 | Pyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof | DYRK1A, DYRK2, DYRK1B | GLI1 1971/4885SMYD3 4499/4885BCHE 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.